Childress Capital Advisors LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 205 shares of the life sciences company’s stock, valued at approximately $76,000.
Other institutional investors have also made changes to their positions in the company. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Illumina in the 4th quarter valued at about $11,424,000. Harvest Volatility Management LLC purchased a new position in Illumina in the 4th quarter valued at about $723,000. Paces Ferry Wealth Advisors LLC boosted its position in Illumina by 3.6% in the 4th quarter. Paces Ferry Wealth Advisors LLC now owns 1,806 shares of the life sciences company’s stock valued at $668,000 after buying an additional 62 shares during the last quarter. Catalyst Private Wealth LLC boosted its position in Illumina by 11.1% in the 4th quarter. Catalyst Private Wealth LLC now owns 1,003 shares of the life sciences company’s stock valued at $371,000 after buying an additional 100 shares during the last quarter. Finally, Voya Financial Advisors Inc. purchased a new position in Illumina in the 4th quarter valued at about $217,000. 89.97% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on the stock. Atlantic Securities lowered shares of Illumina from an “overweight” rating to a “neutral” rating and set a $390.00 target price on the stock. in a research note on Wednesday, March 31st. Cowen upped their target price on shares of Illumina from $385.00 to $460.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. SVB Leerink upped their target price on shares of Illumina from $360.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. Smith Barney Citigroup increased their price objective on shares of Illumina from $330.00 to $335.00 in a research note on Wednesday, December 16th. Finally, BTIG Research increased their price objective on shares of Illumina from $410.00 to $570.00 and gave the stock a “buy” rating in a research note on Tuesday, February 16th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $374.10.
Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 11th. The life sciences company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. The firm had revenue of $953.00 million during the quarter, compared to analysts’ expectations of $949.65 million. Illumina had a net margin of 19.70% and a return on equity of 15.93%. On average, sell-side analysts expect that Illumina, Inc. will post 4.39 EPS for the current fiscal year.
In other news, SVP Susan H. Tousi sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 20th. The shares were sold at an average price of $400.00, for a total transaction of $1,000,000.00. Following the transaction, the senior vice president now owns 40,447 shares in the company, valued at approximately $16,178,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 4,000 shares of the firm’s stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $423.44, for a total transaction of $1,693,760.00. Insiders sold a total of 15,885 shares of company stock valued at $6,463,297 in the last ninety days. Company insiders own 0.38% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.